Video

Dr. Anas Younes on Impact of CheckMate 205 in Classical Hodgkin Lymphoma

Author(s):

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses the phase II CheckMate-205 trial, which looked at single-agent nivolumab (Opdivo) for patients with classical Hodgkin lymphoma (cHL) who had progressed following autologous stem cell transplant (ASCT) and brentuximab vedotin (adcetris).

In the trial, nivolumab induced responses in 66% of patients with cHL. The responses with nivolumab were durable and included 7 complete remissions (CR) and 46 partial remissions (PR). Among the 43 patients who did not respond to brentuximab vedotin, 72% (n = 31) responded to nivolumab.

The duration of response will continue to improve, as many patients are still on trial, but as of now it is about 10-months, says Younes.

These findings remarkable, says Younes, and the impact of nivolumab, which was approved in May, will be significant.

Patients who have progressed following ASCT and brentuximab vedotin, had very few options, says Younes, and many are young patients in the late 20s and early 30s. Nivolumab offers them significant promise for remission, he says.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School